Hospital
Sentara Hospitals
Sentara Hospitals was paid $21.89M by Medicaid between Jan 2018 and Dec 2024, across 200 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
33Billing provider infoSENTARA HOSPITALS
WILLIAMSBURG, VA 23188
WILLIAMSBURG, VA 23188
33aNPI1619938149assigned 04/02/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$21.89M
24GClaims531,573
24DCodes billed200
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#32 of 80
Median peer was paid$14.69M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HANCOCK, MELINDA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 52,372 | $1.27M | |
| 2019 | 75,271 | $1.93M | |
| 2020 | 64,811 | $2.61M | |
| 2021 | 84,713 | $3.41M | |
| 2022 | 90,758 | $4.08M | |
| 2023 | 94,466 | $4.90M | |
| 2024incomplete | 69,182 | $3.68M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 24,622 | 20,808 | $3.99M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 15,159 | 12,481 | $2.46M |
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 8,391 | 5,891 | $2.46M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 6.9% | 10,135 | 3,118 | $1.51M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.3% | 8,711 | 7,123 | $1.38M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.2% | 25,314 | 6,767 | $1.35M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.7% | 6,679 | 5,860 | $1.03M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3.2% | 15,048 | 5,270 | $707K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.8% | 2,987 | 2,637 | $619K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 3,280 | 2,810 | $580K |
| 41899 | Unlisted procedure, dentoalveolar structures | 2.6% | 427 | 378 | $561K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.7% | 1,131 | 1,066 | $379K |
188 more codes
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.7% | 2,731 | $372K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.7% | 3,073 | $362K |
| 97161 | 1.4% | 2,901 | $316K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.4% | 11,194 | $312K |
| G0378 | Hospital observation service, per hour | 1.4% | 1,148 | $310K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.2% | 1,028 | $263K |
| 59025 | Fetal non-stress test | 1.2% | 1,381 | $259K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.0% | 1,194 | $220K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 11,943 | $190K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,894 | $171K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,966 | $170K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 212 | $149K |
| J3490 | Unclassified drugs | <1% | 75,654 | $140K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,643 | $120K |
| 0240U | <1% | 2,138 | $119K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,669 | $94K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,482 | $72K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,782 | $70K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,125 | $70K |
| 80053 | Comprehensive metabolic panel | <1% | 17,659 | $68K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 284 | $68K |
| 97162 | <1% | 616 | $68K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,727 | $53K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,756 | $43K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,139 | $38K |
| 76642 | <1% | 333 | $36K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 620 | $28K |
| 59050 | <1% | 129 | $27K | |
| 97116 | <1% | 1,102 | $25K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 170 | $24K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 22,802 | $24K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 823 | $24K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,113 | $24K |
| 83880 | <1% | 2,260 | $24K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 15 | $22K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 758 | $19K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 25 | $19K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 94 | $19K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 147 | $18K |
| 0225U | <1% | 169 | $18K | |
| 93017 | <1% | 187 | $17K | |
| 71045 | Radiologic examination, chest; single view | <1% | 7,113 | $16K |
| 85379 | <1% | 2,992 | $16K | |
| 87040 | <1% | 2,464 | $16K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,854 | $16K |
| 82962 | <1% | 6,597 | $15K | |
| 81025 | <1% | 3,961 | $15K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 9,908 | $15K |
| 84484 | <1% | 8,679 | $13K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 788 | $11K |
| 93976 | <1% | 163 | $11K | |
| 93971 | <1% | 124 | $11K | |
| 73630 | <1% | 989 | $11K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 32 | $9K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 40 | $9K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,341 | $9K |
| 85027 | <1% | 3,137 | $9K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 589 | $8K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 40 | $8K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,547 | $8K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 582 | $7K |
| 81001 | <1% | 12,572 | $6K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 16 | $6K |
| 83605 | <1% | 5,779 | $6K | |
| 74018 | <1% | 377 | $5K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 70 | $5K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 238 | $5K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,973 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,100 | $5K |
| 83690 | <1% | 5,535 | $4K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 290 | $4K |
| 83735 | <1% | 3,754 | $4K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,780 | $4K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,562 | $4K |
| 87631 | <1% | 187 | $3K | |
| 77066 | Tomosynthesis, mammo | <1% | 95 | $3K |
| 12011 | <1% | 13 | $3K | |
| 80047 | <1% | 709 | $3K | |
| 86900 | <1% | 1,475 | $3K | |
| 72110 | <1% | 193 | $3K | |
| 96376 | <1% | 2,826 | $3K | |
| 81003 | <1% | 6,413 | $3K | |
| 73610 | <1% | 478 | $2K | |
| 85610 | <1% | 2,348 | $2K | |
| 94726 | <1% | 40 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,218 | $2K |
| 71250 | <1% | 24 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,714 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,704 | $2K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 16 | $2K |
| 86850 | <1% | 825 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,701 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,115 | $2K |
| 84703 | <1% | 4,737 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 27 | $2K |
| 77065 | Tomosynthesis, mammo | <1% | 46 | $2K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 12 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,700 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,792 | $2K |
| 73130 | <1% | 236 | $2K | |
| 90715 | <1% | 82 | $2K | |
| 74022 | <1% | 431 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,924 | $2K |
| 76536 | <1% | 13 | $1K | |
| 97016 | <1% | 62 | $1K | |
| 73030 | <1% | 181 | $1K | |
| 92609 | <1% | 52 | $1K | |
| 97166 | <1% | 12 | $1K | |
| 82553 | <1% | 283 | $1K | |
| 94729 | <1% | 39 | $1K | |
| 87081 | <1% | 2,568 | $1K | |
| 73564 | <1% | 205 | $974.47 | |
| 97750 | <1% | 35 | $967.94 | |
| 87186 | <1% | 1,219 | $961.00 | |
| 87077 | <1% | 2,403 | $888.21 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 298 | $885.98 |
| 82565 | <1% | 530 | $839.63 | |
| 86901 | <1% | 1,474 | $811.67 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,233 | $792.05 |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 56 | $708.40 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,219 | $679.26 |
| 87634 | <1% | 53 | $629.44 | |
| 85730 | <1% | 686 | $618.93 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,491 | $539.31 |
| 87210 | <1% | 1,312 | $476.53 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,239 | $419.06 |
| 82803 | <1% | 469 | $415.14 | |
| 80076 | <1% | 347 | $405.44 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,393 | $386.68 |
| 36600 | <1% | 129 | $372.93 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,493 | $364.90 |
| 82077 | <1% | 1,530 | $357.45 | |
| 85014 | <1% | 616 | $341.92 | |
| 84702 | <1% | 354 | $276.52 | |
| 72050 | <1% | 14 | $272.55 | |
| 80061 | Lipid panel | <1% | 120 | $252.83 |
| 73502 | <1% | 40 | $250.84 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,575 | $219.61 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 155 | $204.59 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,435 | $198.20 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 299 | $181.67 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 786 | $179.45 |
| 80143 | <1% | 14 | $160.89 | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 153 | $145.47 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,924 | $129.77 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 622 | $110.00 |
| 73110 | <1% | 25 | $106.64 | |
| 85018 | <1% | 55 | $99.82 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,222 | $92.90 |
| 85652 | <1% | 122 | $68.47 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,399 | $66.80 |
| 87070 | <1% | 217 | $55.55 | |
| G0008 | Administration of influenza virus vaccine | <1% | 141 | $50.95 |
| 84100 | <1% | 161 | $48.58 | |
| 87205 | <1% | 236 | $45.27 | |
| 88304 | <1% | 63 | $42.78 | |
| 82330 | <1% | 49 | $41.34 | |
| 87807 | <1% | 337 | $35.57 | |
| 94799 | <1% | 102 | $30.90 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 305 | $30.76 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 189 | $24.00 |
| 88342 | <1% | 46 | $18.63 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 82 | $7.84 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 32 | $5.38 |
| J1815 | Injection, insulin, per 5 units | <1% | 27 | $5.24 |
| 82550 | <1% | 54 | $5.21 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 51 | $0.96 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 14 | $0.72 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 28 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 29 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 500 | $0.00 |
| 82010 | 0% | 31 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 80 | $0.00 |
| C1729 | Catheter, drainage | 0% | 32 | $0.00 |
| 84145 | 0% | 88 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 69 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 41 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 28 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 149 | $0.00 |
| 94760 | 0% | 33 | $0.00 | |
| C1769 | Guide wire | 0% | 78 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 29 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 142 | $0.00 |
| 36000 | 0% | 15 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 38 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 42 | $0.00 |
| 86140 | 0% | 12 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHANCOCK, MELINDA (CFO)
Parent organizationSENTARA HEALTHCARE
| Provider | Location | Paid |
|---|---|---|
| Sentara Hospitals | Norfolk, VA | $88.20M |
| Sentara Hospitals | Norfolk, VA | $79.69M |
| Sentara Hospitals | Hampton, VA | $78.52M |
| Potomac Hospital Corporation of Prince William | Woodbridge, VA | $59.17M |
| Sentara Hospitals | Suffolk, VA | $57.85M |
| Sentara RMH Medical Center | Harrisonburg, VA | $52.95M |
| Sentara Hospitals | Virginia Beach, VA | $52.40M |
| Sentara Princess Anne Hospital | Virginia Beach, VA | $37.50M |
| Martha Jefferson Hospital | Charlottesville, VA | $26.95M |
| Halifax Regional Hospital, INC. | South Boston, VA | $23.28M |
| Sentara Albemarle Regional Medical Center | Elizabeth City, NC | $13.82M |
| Sentara Reference Lab Solutions, LLC | Norfolk, VA | $4.74M |
| Halifax Regional Hospital, INC | South Boston, VA | $1.61M |
| Halifax Regional Hospital, INC | Nathalie, VA | $348K |
| Halifax Regional Hospital, INC | South Boston, VA | $336K |
| Halifax Regional Hospital, INC | Chase City, VA | $298K |
| Halifax Regional Hospital, INC | Clarksville, VA | $265K |
| Sentara Hospitals | Norfolk, VA | $171K |
| Halifax Regional Hospital, INC | South Boston, VA | $170K |
| Sentara Hospitals | Norfolk, VA | $128K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.